United States - English - NLM (National Library of Medicine)

aytu therapeutics, llc - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, d- (unii: a7e6112e4n) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), levomefolate calcium (unii: a9r10k3f2f) (levomefolic acid - u - cholecalciferol 400 [iu] in 50 ml - fill the dropper to the 1 ml line to provide the full daily dosage. use full dosage, regardless of age or weight, unless your child's doctor recommends a different dosage. dispense with a single squeeze. drops may be given by dispensing directly into the mouth. drops may also be mixed with formula, fruit juice, cereal or other foods to increase your child's acceptance.

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium (unii: sy7q814vup) (calcium - unii:sy7q814vup), phosphorus (unii: 27ylu75u4w) (phosphorus - unii:27ylu75u4w) - cholecalciferol 2000 [iu]

Canada - English - Health Canada

teva canada limited - alendronic acid (alendronate sodium); vitamin d3 (cholecalciferol) - tablet - 70mg; 2800unit - alendronic acid (alendronate sodium) 70mg; vitamin d3 (cholecalciferol) 2800unit - vitamin d

Canada - English - Health Canada

teva canada limited - alendronic acid (alendronate sodium); vitamin d3 (cholecalciferol) - tablet - 70mg; 5600unit - alendronic acid (alendronate sodium) 70mg; vitamin d3 (cholecalciferol) 5600unit - vitamin d

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - cholecalciferol - unknown - cholecalciferol vitamin-d3 active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - alendronic acid 70 mg - fosamax® plus d is indicated for: for the treatment of osteoporosis, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). fosamax plus d alone should not be used to treat vitamin d deficiency. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. the optimal duration of use has not been determined. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see warnings and precautions (5.1)] - inability to stand or sit upright for at least 30 minutes [see dosage and administration (2.3), warnings and precautions (5.1)] - hypocalcemia [see warnings and precautions (5.2)] - hypersensitivity to any component of this product. hypersensitivity reactions including urticaria and angioedema have

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - alendronic acid 70 mg - fosamax® plus d is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] fosamax plus d is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.2)]. fosamax plus d alone should not be used to treat vitamin d deficiency. the optimal duration of use has not been determined. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. fosamax plus d is contraindicated in

United States - English - NLM (National Library of Medicine)

organon llc - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - fosamax® plus d is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] fosamax plus d is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.2)]. fosamax plus d alone should not be used to treat vitamin d deficiency. the optimal duration of use has not been determined. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. fosamax plus d is contraindicated in

United States - English - NLM (National Library of Medicine)

nnodum pharmaceuticals - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol, d- (unii: n9pr3490h9) (.alpha.-tocopherol, d- - unii:n9pr3490h9) -

United States - English - NLM (National Library of Medicine)

guna spa - aloe (unii: v5vd430yw9) (aloe - unii:v5vd430yw9), aluminum oxide (unii: lmi26o6933) (aluminum oxide - unii:lmi26o6933), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), silybum marianum seed (unii: u946sh95ee) (silybum marianum seed - unii:u946sh95ee), chelidonium majus (unii: 7e889u5rnn) (chelidonium majus - unii:7e889u5rnn), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), collinsonia (unii: j9btd5377v) (collinsonia - unii:j9btd5377v), sus scrofa co - aloe 2 [hp_x] in 30 ml - aloe socotrina            2x    laxative alumina                6x 8x    constipation bryonia alba            6x 8x    spasmolytic carduus marianus        2x    supports digestion chelidonium majus        2x    supports digestion cholecalciferol            2x    antioxidant collinsonia canadensis        2x    hemorrhoids colon                6x 12x 30x    stimulates digestion kali carbonicum            6x 8x 12x    back pain natrum carbonicum        6x 8x 12x    bloating after eating niacin                2x    regulates cholesterol nux vomica            6x 8x    helps digestion pantothenic acid        2x    stimulates digestion rectum                6x 12x 30x